Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Investor interest in 4d Pharma PLC (LON: DDDD) shares spiked higher earlier today after the company announced its top executives would participate in a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021.
However, the interest did not materialise into a stock rally as the biotech company’s shares continued trading sideways after the UK markets opened.
4d Pharma’s CEO, Duncan Peyton and Chief Scientific Officer, Alex Stevenson, will present the firm’s latest corporate overview at the virtual event, after which they will participate in a fireside chat with the organisers.
Some of the potential highlights of the presentation and fireside chat could include the company’s successful dual-listing on the NASDAQ in March 2021, which happened despite the coronavirus restrictions that hampered international travel.
4d Pharma may also mention the progress made in developing a treatment fr Parkinsons disease, which is in the pre-clinical stages following its partnership with the Michael J White Foundation and Parkinson’s UK.
The biotech company is pioneering a new class of medicines based on the human microbiome to treat neurodegenerative diseases, cancers and asthma. The firm has made substantial progress towards the first human trials of its Parkinson’s drug.
The live biotherapeutics company has finished enrolling participants into the phase I/II trial of its asthma treatment MRx-4DP0004. It expects to announce the first data set from study participants before the end of Q3.
4d Pharma has partnerships with global pharma companies Merk and Pfizer to evaluate the effectiveness of its MRx0518 drug in treating urotherial carcinomas at advanced stages in patients that are not responsive to other treatments.
MRx0518 is being paired with KEYTRUDA for the study, with initial results being quite positive.
From a technical perspective, 4d Pharma shares are trading in the middle of a wide trading range, which does not provide excellent trade setups since the shares could move in either direction.
I would be looking to but at the bottom of the range while selling at the top.
*This is not investment advice.
4d pharma share price.
4d Pharma shares are down 23.02% in 2021 amid a broader selloff in last year’s growth stocks.
4d Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are 4d Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .